Atong AbrahamOwiny Augustine OkejomoeNamisi Patrick CharlesSebunya Robert2026-11-202026-11-202026-10-05Atong, A., Okejomoe, O.A., Namisi, C.P. and Sebunya, R. (2026) 'Prevalence and clinical correlates of antiseizure medication polytherapy among children and adolescents attending a specialist paediatric neurology clinic in Uganda', Research Square [Preprint]. Available at: doi.org/10.21203/rs.3.rs-10787608/v1http://hdl.handle.net/20.500.12280/3393Background Antiseizure medication (ASM) monotherapy is generally preferred for childhood epilepsy, but somechildren require two or more ASMs because of persistent seizures, epilepsy syndrome, treatmenttransition or greater clinical complexity. Contemporary Ugandan data on the frequency and clinicalcorrelates of paediatric ASM polytherapy are limited. Objective To determine the prevalence of current ASM polytherapy and identify clinical factors associated withpolytherapy among children and adolescents attending a specialist paediatric neurology clinic inUganda. Methods We conducted a cross-sectional analysis of retrospectively abstracted clinical data from 496 childrenand adolescents aged 1–18 years with epilepsy attending the Paediatric Neurology Clinic at St. FrancisHospital Nsambya, Kampala, Uganda. Current ASM regimen was classified as monotherapy orpolytherapy. Modified Poisson regression with robust standard errors was used to estimate crude andadjusted prevalence ratios (PRs) with 95% confidence intervals (CIs). Results Seventy-eight of 496 participants were recorded as receiving polytherapy, giving a prevalence of 15.7%(95% CI 12.8–19.2). In the primary adjusted model, generalized epilepsy was associated with a higherprevalence of recorded polytherapy than focal epilepsy (aPR 2.62, 95% CI 1.70–4.04; p < 0.001), whileany documented comorbid condition was associated with approximately twice the prevalence (aPR 2.01,95% CI 1.25–3.23; p = 0.004). Medication-name review classified 64/496 (12.9%) as receiving at leasttwo recognizable ASMs; agreement with the recorded regimen classification was 92.7% (Cohen's kappa0.70). In this sensitivity analysis, the association with comorbidity remained strong (aPR 2.65; p < 0.001),whereas the generalized-epilepsy association attenuated to borderline statistical significance (aPR 1.60;p = 0.050). Conclusion Approximately one in six children and adolescents were recorded as receiving ASM polytherapy.Comorbidity was the most robust clinical correlate across outcome definitions. The association with generalized epilepsy was sensitive to how polytherapy was classified, highlighting the importance ofstandardized medication reconciliation in retrospective epilepsy research.enhttps://creativecommons.org/licenses/by/4.0/EpilepsyAntiseizure medicationPolytherapyMonotherapyINTERDISCIPLINARY RESEARCH AREAS::ChildrenUgandaPrevalence and clinical correlates of antiseizuremedication polytherapy among children andadolescents attending a specialist paediatricneurology clinic in UgandaArticlehttps://doi.org/10.21203/rs.3.rs-10787608/v1